Tower Research Capital (TRC)’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-896
| Closed | -$19.2K | – | 6200 |
|
|
2024
Q1 | $19.2K | Buy |
+896
| New | +$5.94K | ﹤0.01% | 3032 |
|
|
2023
Q4 | – | Sell |
-1,180
| Closed | -$4.58K | – | 6402 |
|
|
2023
Q3 | $4.58K | Sell |
1,180
-362
| -23% | -$1.41K | ﹤0.01% | 4844 |
|
|
2023
Q2 | $6.49K | Sell |
1,542
-584
| -27% | -$1.85K | ﹤0.01% | 4699 |
|
|
2023
Q1 | $6K | Buy |
2,126
+352
| +20% | +$1.3K | ﹤0.01% | 4918 |
|
|
2022
Q4 | $9K | Buy |
1,774
+772
| +77% | +$2.96K | ﹤0.01% | 4338 |
|
|
2022
Q3 | $7K | Buy |
1,002
+36
| +4% | +$312 | ﹤0.01% | 4968 |
|
|
2022
Q2 | $7K | Buy |
966
+369
| +62% | +$3.36K | ﹤0.01% | 4862 |
|
|
2022
Q1 | $9K | Buy |
597
+200
| +50% | +$5.09K | ﹤0.01% | 4526 |
|
|
2021
Q4 | $19K | Buy |
397
+332
| +511% | +$34.9K | ﹤0.01% | 3760 |
|
|
2021
Q3 | $10K | Sell |
65
-78
| -55% | -$10.1K | ﹤0.01% | 4374 |
|
|
2021
Q2 | $16K | Buy |
143
+42
| +42% | +$4.68K | ﹤0.01% | 4100 |
|
|
2021
Q1 | $10K | Buy |
+101
| New | +$13.2K | ﹤0.01% | 4393 |
|
Tower Research Capital (TRC)'s LABP Position: Q2 2024 in Review
Tower Research Capital (TRC) sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 896 shares — an estimated $19.2K sold.
Tower Research Capital (TRC) first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $19.2K in Q1 2024. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.
- Tower Research Capital (TRC) reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 896 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $19.2K.
- Tower Research Capital (TRC) first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Tower Research Capital (TRC)'s Landos Biopharma, Inc. Common Stock position peaked at $19.2K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.